منابع مشابه
Newer Antidiabetic Drugs
The current oral blood glucose lowering agents and dietary measures only partially correct the multiple metabolic defects in NIDDM with insulin resistance remaining relatively impervious to treatment Hypoglycaemia and secondary failure are common with presently available sulphonylureas and hence the need for newer blood glucose lowering drugs. In case of NIDDM, a successful new drug should corr...
متن کاملPharmacogenetics of Oral Antidiabetic Drugs
Oral antidiabetic drugs (OADs) are used for more than a half-century in the treatment of type 2 diabetes. Only in the last five years, intensive research has been conducted in the pharmacogenetics of these drugs based mainly on the retrospective register studies, but only a handful of associations detected in these studies were replicated. The gene variants in CYP2C9, ABCC8/KCNJ11, and TCF7L2 w...
متن کاملOral Antidiabetic Drugs for Cats
Diabetes mellitus (DM) is commonly diagnosed in cats. In humans, treatment regimens for non–insulin-dependent DM include various combinations of dietary modification, exercise, insulin administration, and one or more oral antidiabetic drugs, which have been extensively evaluated in humans but not in cats. Glucose toxicity is a phenomenon of chronic hyperglycemia and must be understood before in...
متن کاملMechanism of action of oral antidiabetic drugs.
The fall in blood sugar with carbutamide (BZ55) 24 hr. after the maintenance dose of insulin (28.1%+/-2.9 s.e) in rabbits made severely diabetic with alloxan was significantly different from the change in the blood sugar with the same drug given 72 hr. (6.8%+/-2.0) or distilled water given 24 hr. (7.7%+/-1.3) respectively after the last dose of insulin. It is postulated that the drug acts by li...
متن کاملThe Current Status of New Antidiabetic Drugs
Dear Editor, Type 2 diabetes mellitus (T2DM) is a world-wide public health problem [1]. As such, the Food and Drug Administration (FDA), pharmaceutical companies and medical researchers/practitioners should be discussing the costs vs. the benefits for economically-disadvantaged populations that are disproportionately affected by T2DM and, therefore, suffering the most [2]. The current debate ab...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Interní medicína pro praxi
سال: 2016
ISSN: 1212-7299,1803-5256
DOI: 10.36290/int.2016.036